60 yo with obvious progression within a few months of FOLFOX/bev?
What systemic treatment would you most likely recommend for the following patients:
A 60-year-old patient with asymptomatic mCRC receives FOLFOX/bevacizumab but within a few months experiences obvious disease progression. The tumor is KRAS wild type.
Same as above, but the tumor is KRAS mutant?
Arnold D et al. New developments in the second-line treatment of metastatic colorectal cancer: Potential place in therapy. Drugs 2013;73(9):883-91. Abstract
Barni S et al. Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: A pooled analysis and review of literature. Rev Recent Clin Trials 2013;[Epub ahead of print]. Abstract
Bennouna J et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37. Abstract
Fakih M. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther 2013;13(4):427-38. Abstract
Lange A et al. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer 2013;[Epub ahead of print]. Abstract
Van Cutsem E et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506. Abstract